PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424419
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424419
Global sacral nerve stimulation market size is expected to reach US$ 634.1 Mn by 2030, from US$ 422.7 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 6% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 422.7 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 6.00% | 2030/2031 Value Projection: | US$ 634.1 Mn |
Sacral nerve stimulation (SNS) is a minimally invasive procedure that involves placing a small medical device called an implantable neurostimulator to treat bladder, bowel, and pelvic floor disorders.
There are two types of sacral nerve stimulation systems - tined lead and paddle lead systems. Tined lead systems involve the insertion of a thin wire with tiny electrodes at the tip, called a lead, through the skin into the S3 sacral foramen area under imaging guidance. The lead is then attached to an internal pulse generator which is implanted in the lower butt area. Paddle lead systems involve surgically placing a lead with a flat, soft paddle at its tip which sits directly on the sacral nerve.
Both systems work by sending mild electrical pulses to the sacral nerves that control bowel and bladder function. This disrupts the abnormal signals causing symptoms and restores normal function. Sacral nerve stimulation has shown significant success in improving symptoms of overactive bladder, fecal incontinence, and chronic pelvic pain. Some advantages include being minimally invasive, with a adjustable therapy that can be turned on or off, byproviding improvements within days of being turned on. However, the implants do require permanent surgical placement and eventual battery replacement surgery. There is also a chance of leads moving out of optimal position long-term.
Market Dynamics:
Global sacral nerve stimulation market is mainly driven by the increasing prevalence of chronic devices. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in December 2018, the global chronic pain prevalence survey found that 19.3% Indian adult population suffers from cerebral palsy.